Normosang (Human Hemin)

Human hemin supplies the body with heme, which feeds back to inhibit aminolevulinic acid synthase (ALAS), the first enzyme in the porphyrin‑making pathway. By down‑regulating ALAS, production of aminolevulinic acid and porphobilinogen falls, reducing the accumulation of neurotoxic precursors that trigger acute porphyria symptoms.

The dose of Normosang is individualized and determined by the treating physician based on the severity of the porphyria attack, patient weight, renal function and clinical response. Prescribers calculate the appropriate amount and infusion rate, and the regimen may be adjusted during the course of therapy.

Safety data for human hemin in pregnancy and lactation are limited. The product should be used only when the potential benefit to the mother outweighs any possible risk to the fetus or infant. Clinicians should discuss the uncertainty with the patient and consider alternative management strategies when possible.

To request Normosang, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if needed) and any required import documentation.

The primary alternative to Normosang is heme arginate (Panhematin). Both deliver exogenous heme and act by suppressing ALAS activity, but formulation, dosing schedules and regulatory status differ. Normosang is supplied as a sterile intravenous solution, while heme arginate is typically provided as a lyophilized powder for reconstitution. Choice often depends on local availability, physician preference and specific patient factors.

Normosang must be stored refrigerated at 2‑8 °C. It should be kept in its original container, protected from light, and must not be frozen or shaken. Before use, inspect the vial for particulate matter or discoloration and allow the solution to reach room temperature if required for infusion.

Normosang is administered by intravenous infusion under medical supervision. The vial is diluted with an appropriate compatible solution, and the infusion is delivered over a period typically ranging from 30 minutes to several hours, depending on the prescribed dose and patient tolerance. Monitoring of vital signs during infusion is recommended.

The most serious adverse reactions include acute hemolytic anemia, severe allergic reactions such as anaphylaxis, and rare thromboembolic events. Early signs such as sudden drop in hemoglobin, respiratory distress, urticaria, hypotension or unexplained pain should prompt immediate medical evaluation and discontinuation of the infusion.

Normosang is contraindicated in patients with known hypersensitivity to human hemin or any excipients in the formulation. Caution is advised in individuals with severe renal impairment, uncontrolled hypertension, or a history of severe allergic reactions to intravenous products. The drug should also be avoided in patients for whom alternative, non‑heme therapies are appropriate.